Eberle Andrea, Jansen Lina, Castro Felipe, Krilaviciute Agne, Luttmann Sabine, Emrich Katharina, Holleczek Bernd, Nennecke Alice, Katalinic Alexander, Brenner Hermann
Bremen Cancer Registry, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lung Cancer. 2015 Dec;90(3):528-33. doi: 10.1016/j.lungcan.2015.10.007. Epub 2015 Oct 20.
Lung cancer is the most common cancer-related death worldwide. In Germany it accounts for 25% of cancer deaths in men, and 14% in women. The aim of this study is to provide an overview of 5-year relative survival by sex, age, histology, and tumour stage in Germany representing a population of 26.7 million people.
The study is based on a pooled German dataset including data from 12 population-based cancer registries covering around one third of the German population. A total of 132,612 patients diagnosed with lung cancer from 2002 to 2010 were included in the analysis. Survival estimates for the time period 2007-2010 were calculated using period analysis. Differences in survival between sexes were tested for statistical significance by model-based period analysis (poisson regression model). The relative excess risk (RER) of death (women vs. men) was extracted from the model with the p value for the difference in RER.
The overall age adjusted 5-year relative survival was 15.5% (standard error (SE) 0.2) for men and 20.3% (SE 0.3) in women. Survival differed markedly according to age (men: <60 years 18.5% vs. 80+ years 8.4% and women 23.7% vs. 10.6%, respectively), histology (largest difference between histological groups: men 25.7 and women 44.4% points) and stage (men: UICC Ia 62.9%, vs. UICC IV 4.6% and women 75.2% vs. 7.0%, respectively). Our study showed survival advantages for women compared to men, most notably in younger aged patients (RER 0.83, p<0.0001), patients with adenocarcinoma (RER 0.80, p<0.0001), and patients with lower stage cancer (RER 0.62, p<0.0001).
This study presents up-to-date survival estimates for lung cancer in Germany. Compared to other European countries survival was relatively high. Women showed higher survival than men independent of age, histology and stage. The reasons for the survival differences require further clarification.
肺癌是全球癌症相关死亡的最常见原因。在德国,肺癌占男性癌症死亡人数的25%,占女性的14%。本研究旨在概述德国按性别、年龄、组织学和肿瘤分期划分的5年相对生存率,德国人口约为2670万。
本研究基于一个汇总的德国数据集,该数据集包括来自12个基于人群的癌症登记处的数据,覆盖了约三分之一的德国人口。分析纳入了2002年至2010年期间共132612例被诊断为肺癌的患者。使用时期分析计算2007 - 2010年期间的生存估计值。通过基于模型的时期分析(泊松回归模型)检验性别间生存率差异的统计学意义。从模型中提取死亡的相对超额风险(女性与男性相比)以及相对超额风险差异的p值。
总体年龄调整后的5年相对生存率男性为15.5%(标准误(SE)0.2),女性为20.3%(SE 0.3)。生存率根据年龄(男性:<60岁为18.5%,80岁及以上为8.4%;女性分别为23.7%和10.6%)、组织学(组织学组间最大差异:男性为25.7个百分点,女性为44.4个百分点)和分期(男性:国际抗癌联盟(UICC)Ia期为62.9%,UICC IV期为4.6%;女性分别为75.2%和7.0%)有显著差异。我们的研究表明,与男性相比,女性具有生存优势,在年轻患者中(相对超额风险0.83,p<0.0001)、腺癌患者中(相对超额风险0.80,p<0.0001)以及癌症分期较低的患者中(相对超额风险0.62,p<0.0001)尤为明显。
本研究给出了德国肺癌最新的生存估计值。与其他欧洲国家相比,生存率相对较高。无论年龄、组织学和分期如何,女性的生存率均高于男性。生存差异的原因需要进一步阐明。